Protein Signature of Lung Cancer Tissues

Lung cancer remains the most common cause of cancer-related mortality. We applied a highly multiplexed proteomic technology (SOMAscan) to compare protein expression signatures of non small-cell lung cancer (NSCLC) tissues with healthy adjacent and distant tissues from surgical resections. In this first report of SOMAscan applied to tissues, we highlight 36 proteins that exhibit the largest expression differences between matched tumor and non-tumor tissues. The concentrations of twenty proteins increased and sixteen decreased in tumor tissue, thirteen of which are novel for NSCLC. NSCLC tissue biomarkers identified here overlap with a core set identified in a large serum-based NSCLC study with SOMAscan. We show that large-scale comparative analysis of protein expression can be used to develop novel histochemical probes. As expected, relative differences in protein expression are greater in tissues than in serum. The combined results from tissue and serum present the most extensive view to date of the complex changes in NSCLC protein expression and provide important implications for diagnosis and treatment.

[1]  V. Cogliano International Agency for Research on Cancer (IARC) , 2018, The Grants Register 2019.

[2]  M. L. R. D. Christenson,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[3]  S. Digumarthy,et al.  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Kwon-Sik Park,et al.  Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. , 2011, Cancer cell.

[5]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[6]  Iver Petersen,et al.  IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. , 2011, Lung cancer.

[7]  J. Ioannidis,et al.  Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. , 2011, JAMA.

[8]  P. Bossuyt The thin line between hope and hype in biomarker research. , 2011, JAMA.

[9]  Sheri K. Wilcox,et al.  Rapid Histochemistry Using Slow Off-rate Modified Aptamers With Anionic Competition , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[10]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[11]  Ugo Pastorino,et al.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.

[12]  E. Diamandis,et al.  Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.

[13]  K. Hirata,et al.  Role of endothelial cell-selective adhesion molecule in hematogeneous metastasis. , 2010, Microvascular research.

[14]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[15]  Stephen A. Williams,et al.  Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.

[16]  L. Puricelli,et al.  Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. , 2010, Human pathology.

[17]  C. Reed,et al.  Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. , 2010, The Journal of thoracic and cardiovascular surgery.

[18]  Y. Ishikawa,et al.  Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. , 2010, The American journal of pathology.

[19]  L. Tanoue,et al.  Molecular Origins of Cancer. Lung Cancer , 2010 .

[20]  J. Wang,et al.  Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. , 2010, Neoplasma.

[21]  Soo Young Lee,et al.  MicroRNA Expression Profiles in Korean Non-Small Cell Lung Cancer , 2009 .

[22]  J. Roth,et al.  Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. , 2009, The Journal of thoracic and cardiovascular surgery.

[23]  Masato Nakamura,et al.  Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma. , 2009, Oncology reports.

[24]  O. Topolcan,et al.  Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. , 2009, Anticancer research.

[25]  D. Beer,et al.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. , 2009, Neoplasia.

[26]  L. Qian,et al.  Microvessel Density and Expression of Thrombospondin-1 in Non-small Cell Lung Cancer and Their Correlation with Clinicopathological Features , 2009, The Journal of international medical research.

[27]  Polina Golland,et al.  Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning , 2009, Proceedings of the National Academy of Sciences.

[28]  C. Lee,et al.  Caspase‐3 enhances lung metastasis and cell migration in a protease‐independent mechanism through the ERK pathway , 2008, International journal of cancer.

[29]  M. Schmitt,et al.  Expression of metalloprotease insulin-degrading enzyme (insulysin) in breast and ovarian cancer tissues , 2008 .

[30]  W. Sessa,et al.  Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. , 2008, The American journal of pathology.

[31]  B. Jeon,et al.  Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. , 2008, Lung cancer.

[32]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[33]  J. Soria,et al.  Gene expression profiling of non-small-cell lung cancer , 2008, Expert review of molecular diagnostics.

[34]  M. Schmitt,et al.  Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues. , 2008, International journal of molecular medicine.

[35]  Cheng-Long Huang,et al.  Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. , 2007, Lung cancer.

[36]  Lin Feng,et al.  Identification of genes differentially expressed in human primary lung squamous cell carcinoma. , 2007, Lung cancer.

[37]  M. Pacyna‐Gengelbach,et al.  Insulin‐like growth factor binding protein‐related protein 1 (IGFBP‐rP1) has potential tumour‐suppressive activity in human lung cancer , 2007, The Journal of pathology.

[38]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[39]  G. Watanabe,et al.  Surgical results in T2N0M0 nonsmall cell lung cancer patients with large tumors 5 cm or greater in diameter: what regulates outcome? , 2006, The Annals of thoracic surgery.

[40]  S. Burdach,et al.  Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array. , 2006, Oncology reports.

[41]  N. Sun,et al.  Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. , 2006, The Annals of thoracic surgery.

[42]  G. Cavet,et al.  Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.

[43]  N. Carter,et al.  Genome-Wide Screening of Genomic Alterations and Their Clinicopathologic Implications in Non–Small Cell Lung Cancers , 2005, Clinical Cancer Research.

[44]  Raphael A Nemenoff,et al.  Tumorigenesis and Neoplastic Progression Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model , 2010 .

[45]  Günther Richter,et al.  Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Rolf-Edgar Silber,et al.  Down-regulation of the Receptor for Advanced Glycation End-products (rage) Supports Non-small Cell Lung Carcinoma , 2004 .

[47]  M. Okada,et al.  Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. , 2005, The Journal of thoracic and cardiovascular surgery.

[48]  M. Tada,et al.  Prediction of lymph node metastasis by analysis of gene expression profiles in non-small cell lung cancer. , 2004, The Journal of surgical research.

[49]  Hoon-Kyo Kim,et al.  Expression of caspase-3 and c-myc in non-small cell lung cancer. , 2004, Cancer research and treatment : official journal of Korean Cancer Association.

[50]  K. Hiroshima,et al.  Overexpression of Collagen XVIII Is Associated with Poor Outcome and Elevated Levels of Circulating Serum Endostatin in Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[51]  Jianzhong Su,et al.  Quantitative detection of interleukin 8 gene expression in lung cancer by real—time polymerase chain reaction , 2004 .

[52]  T. Hiwasa,et al.  Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma , 2004, Cancer.

[53]  S. Wiseman,et al.  Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry , 2004, Modern Pathology.

[54]  P. Allavena,et al.  From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. , 2004, Critical reviews in immunology.

[55]  H. Kato,et al.  cDNA microarray analysis of gene expression in pathologic stage IA nonsmall cell lung carcinomas , 2003, Cancer.

[56]  B. Stewart,et al.  World Cancer Report , 2003 .

[57]  David E. Misek,et al.  RANTES expression is a predictor of survival in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  John D. Storey A direct approach to false discovery rates , 2002 .

[59]  E. Gabrielson,et al.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Yih-Leong Chang,et al.  The significance of E-cadherin and α-, β-, and γ-catenin expression in surgically treated non–small cell lung cancers of 3 cm or less in size , 2002 .

[61]  I. Shimon,et al.  Elevated Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-2 in Malignant Pleural Effusion , 2002, Acta oncologica.

[62]  Yih-Leong Chang,et al.  The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. , 2002, The Journal of thoracic and cardiovascular surgery.

[63]  S. Erzurum,et al.  Differential expression of manganese superoxide dismutase and catalase in lung cancer. , 2001, Cancer research.

[64]  B. Rybarczyk,et al.  Tumors and Fibrinogen , 2001, Annals of the New York Academy of Sciences.

[65]  P. Bornstein,et al.  Thrombospondin 2, a matricellular protein with diverse functions. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[66]  A. Yuan,et al.  Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. , 2000, American journal of respiratory and critical care medicine.

[67]  J. Foekens,et al.  The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  J. Foekens,et al.  The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  E. Brambilla,et al.  Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  C. Angeletti,et al.  Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas , 1999, British Journal of Cancer.

[71]  C. Angeletti,et al.  Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  Y. Oshika,et al.  Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  K. Yasumoto,et al.  Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. , 1998, The Journal of thoracic and cardiovascular surgery.

[74]  P. Schraml,et al.  Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. , 1997, Cancer research.

[75]  G. Fontanini,et al.  607 Vascular endothelial growth factor (VEGF) in non small cell lung carcinomas (NSCLC): Prognostic implications , 1997 .

[76]  G. Jaques,et al.  Molecular cloning of IGFBP-5 from SCLC cell lines and expression of IGFBP-4, IGFBP-5 and IGFBP-6 in lung cancer cell lines and primary tumours. , 1993, European journal of cancer.

[77]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[78]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.